PerkinElmer company Euroimmun has launched CE marked PCR test, EURORealTime SARS-CoV-2/Influenza A/B, for detecting SARS-CoV-2 and influenza virus type A and type B.

With the latest development, the company strengthened its portfolio for acute Covid-19 diagnostics by supporting differential diagnostics between SARS-CoV-2 infections and common flu.

PCR technology is seen as the gold standard for direct detection of pathogens.

The test helps in fast identification and differentiation of genetic material from SARS-CoV-2 and influenza virus type A and type B.

EURORealTime SARS-CoV-2/Influenza A/B assay uses throat swab samples collected from patients with acute symptoms indicative for Covid-19 or flu.

Results obtained with the latest test and those from reference PCR tests for SARS-CoV-2 and influenza A/B were similar, validation efforts showed.

In addition, cross-reactions with other common respiratory pathogens were not observed.

Euroimmun CEO Dr Wolfgang Schlumberger said: “Individuals with these viral diseases can present with very similar symptoms, which makes it difficult to differentiate between them.

“Here, direct pathogen detection plays a major role in the rapid and correct identification of these infections as it is essential for proper subsequent patient management.

“The combination of the three pathogens within this single multiparametric assay means saving valuable time and resources in the laboratories.”

Compatible with common real-time PCR thermal cyclers, with the help of EURORealTime Analysis Software, the assay provides a consistent and standardised analysis of the test results.

The assay complements the CE marked PerkinElmer’s PKamp Respiratory SARS-CoV-2 RT-PCR Panel.

The EURORealTime SARS-CoV-2/Influenza A/B assay is the second molecular assay by Euroimmun for direct pathogen detection.

Earlier, EURORealTime SARS-CoV-2 assay received CE marking and the US Food and Drug Administration (FDA) emergency use authorisation (EUA).

In May, Euroimmun received the FDA EUA for Anti-SARS-CoV-2 ELISA (IgG) serology test to identify Covid-19 antibodies.